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ABSTRACT
Gastroesophageal reflux disease (GERD), or acid reflux, affects 6-9 million people in the United
States. It is characterized by a reflux of gastric acid and bile salts from the stomach into the
esophagus, causing injuries to the esophagus known as Barrett’s esophagus (BE). BE is the main
risk factor for the development of esophageal adenocarcinoma (EAC), a devastating cancer in the
esophagus whose molecular roots remain poorly understood. In recent years, evidence points to
the esophageal epithelium itself as responsible for causing and promoting inflammation upon
injury by gastric reflux, namely via an increase in inflammatory cytokine secretion. This project
was focused on a cytokine of interest, Activin A, which is known for its importance during
embryogenesis and stem cell differentiation. It has recently been studied for its role in
inflammation and tumor formation, but not in the case of esophageal diseases. Here, we
demonstrate that Activin A signaling in esophageal epithelial cells is heavily upregulated shortly
after exposure to bile salts and acid. We show evidence that this upregulation causes an increase
in cell migration upon a reconstituted extracellular matrix. We also provide further evidence that
bile and acid injury causes epithelial cells to secrete cytokines, which drive inflammation. We
show that the upregulated Activin A secretion and signaling plays an important role in promoting
this inflammatory state. Finally, we provide evidence that bile salts and acid exposure, as well as
increased Activin A signaling, causes esophageal epithelial cells to upregulate stem cell and
transdifferentiation markers, supporting the latest theories on the origin of Barrett’ esophagus
stem cells as well as paligenosis.
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INTRODUCTION
Esophageal adenocarcinoma (EAC) is a serious cancer of the distal esophagus. Its incidence has
dramatically increased in developed nations over the past 40 years, and it is now the sixth most
common cause of cancer-related deaths worldwide and eleventh in the United States1, 2. EAC is a
difficult cancer to manage and its 5-year survival rate is below 20%2.
One of the most well-known risk factors for EAC is gastroesophageal reflux disease (GERD),
also known as gastric reflux or acid reflux. GERD affects approximately 6-9 million people in
the United States3, and when acute is commonly referred to as heart burn. GERD is caused by
the chronic reflux of gastric contents including acids and bile salts from the stomach into the
esophagus. The prolonged exposure of normal esophageal epithelium to these harsh gastric
chemicals causes a metaplastic change from a stratified squamous epithelium to an intestinal
columnar epithelium called Barrett’s esophagus (BE). Multiple studies have shown that BE is
one of the main factors for the development of EAC4.
Much remains to be learned about the development and progression from GERD to EAC.
Particularly, the biochemical and molecular roots of this progression remain largely unknown.
The main goal of this research project was to evaluate one particular cell signaling pathway,
namely Activin A signaling, at the onset of GERD. Dysregulation of Activin A signaling has
been shown to promote lung cancer and colorectal cancer, but its role is poorly defined for EAC.
Particularly, Activin A signaling has never been studied in the context of GERD-related diseases,
and its role in the progression from normal esophageal epithelium to Barrett’s esophagus is
unknown.
1

The work presented here has shed light on the topic of Activin A signaling in GERD-related
diseases. Our findings have elucidated the effects of GERD-like injuries on Activin A signaling.
We have described the role of Activin A signaling in the inflammatory signaling response caused
by bile salts and acid in esophageal epithelial cells. Finally, we contributed to the latest work
done in the field of gastroesophageal diseases, particularly on the theories of precursor cells for
Barrett’s esophagus.
The data presented in this project will be able to directly impact the latest areas of
gastroesophageal research including the signaling pathways involved in the GERD to EAC
progression, the theories on the origin of BE stem cells, as well as the theories on cellular
reprogramming and paligenosis5. Together, we hope that this new information will lead to a
better understanding of the onset of gastroesophageal diseases and potentially new therapeutic
strategies.
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BACKGROUND AND SIGNIFICANCE
Since 1975, the incidence of esophageal adenocarcinoma (EAC) has increased as much as 460%
throughout Europe and North America1. It presents many challenges, including poor survival
rates due to late diagnosis and lack of effective screening methods4, 6. The risk factors for EAC
include tobacco smoking, obesity, advanced age, and most importantly gastroesophageal reflux
disease (GERD). In GERD, acidic contents from the stomach spill into the esophagus, thereby
injuring the epithelial lining and causing heartburn to the patient. Over time, exposure to the
acidity and other secretions such as bile salts results in injuries to the esophageal epithelium.
Consequently, the squamous epithelium experiences a histological transition to an intestinal
columnar epithelium, otherwise known as Barrett’s esophagus (BE). Barrett’s and GERD are
major risk factors for EAC. Studies have shown that patients with chronic GERD have between a
5-fold to 8-fold increased risk of developing EAC7, 8, 9. In summary, the development of EAC
from normal esophageal epithelium follows an overall pattern:

Figure 1: GERD to EAC progression.

The earliest theories about this progression hypothesized that the state of inflammation found in
GERD and BE could be explained solely by the physical injuries caused by the acid exposure in
the esophagus. It was thought that the refluxing stomach acid caused a physical degradation of
the tissue and an open wound in the esophageal epithelium. It was thought that the cells that
came in and replaced the damaged tissue were metaplastic, intestinal-like cells characteristic of
3

BE. The wound healing process was also responsible for recruiting more immune cells and
promoting the state of inflammation see in BE10.
In recent years, this theory has been largely replaced and as more evidence points to the
importance of the injured epithelium as the key factor for inducing the inflammatory response.
Following reflux from stomach contents on the esophageal epithelium, epithelial cells actually
do not undergo early apoptosis and get replaced. Instead, there is an abundance of evidence that
injured cell are triggered to produce inflammatory cytokines, which then attract the immune cells
and cause the observed inflammatory response10-13.
We now know that inflammatory cytokines produced by acid and bile-injured epithelial cells
play an important role in promoting inflammation and disease progression shown in figure 1. In
addition, molecular mechanisms that drive the progression have been reported, and the impact of
acid and bile salts at various parts of this progression have been studied in the past as well.
For example, acid exposure has been shown to significantly reduce apoptosis and increase the
proliferation of esophageal adenocarcinoma cells via disruption of p53-dependent mechanisms,
as well as disruption of the mitogen-activated protein kinase (MAPK) pathways, which are
involved in cell growth regulation14, 15. In such way, bile salts may have an important role in the
uncontrolled proliferation of esophageal adenocarcinoma cells. Bile salts have also been shown
to increase the proliferation of Barrett’s cells through the same MAPK pathways, indicating that
dysregulation of these pathways could play an important role in the progression of the cancer16.
In addition, the homeobox protein CDX-2, which is expressed as a result of the GERD and
tightly associated with the emergence of Barrett’s metaplasia, has been shown to play a pivotal
4

role in the intestinal differentiation of esophageal epithelial cells to columnar Barrett’s cells upon
exposure to various bile acids17. NFκB transcription factors are important mediators of
inflammation. Two NFκB transcription factor binding sites in the CDX2 promotor were also
shown to regulate the differentiation effect of CDX-2 itself17, therefore contributing to the
progression of the cancer.
Finally, DNA damage caused by the components of the gastric refluxate has been shown to
contribute to the progression of esophageal adenocarcinoma. Indeed, normal esophageal cells
exposed to bile salts such as sodium glycocholate, glycocholic acid, sodium taurocholate, and
taurochenodeoxycholate show a significant increase in DNA damage that contribute to the
overall the progression of the cancer18.
The studies mentioned above are important findings that give us valuable insight into the
progression from GERD to EAC. However, these studies, as well as most research in the field of
gastroesophageal diseases to date, have focused on the latter part of the progression, namely BE
to EAC. Indeed, the majority of research about this topic involves studies on metaplastic
Barrett’s esophagus cell lines or directly esophageal adenocarcinoma cells themselves. The
clinical studies also mostly involve patients with esophagitis or already diagnosed with BE or
EAC. Only a small amount of research has been dedicated to the onset of the disease, when
esophageal epithelial cells are still normal and the chronic acid reflux is beginning to take place.
This is the area that this research project addressed.
In recent years, Activin A, a regulatory cytokine that is part of the transforming growth factor β
(TGFβ) superfamily, has been increasingly studied for its role in carcinogenesis. Activin A is a
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protein composed of two Activin βA subunits that join to form a dimer (βAβA). Two membranebound, Activin A-specific receptors (Activin Receptors IB and IIB – ACRIB and ACRIIB)
regulate its cellular signaling via different pathways.
Activin A signaling is known to proceed through a canonical and non-canonical pathway19
(figure 2 – A-B). The canonical pathway involves the Smad proteins as direct targets. Upon
Activin A binding to the receptor, Smad2/3 gets phosphorylated and a complex with Smad4 is
formed. This complex is translocated to the nucleus, where it will bind DNA and affect gene

Figure 2: Canonical and non-canonical pathways of Activin A signaling.
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transcription. The non-canonical pathway mediates the signal through a different set of
intermediates, namely the mitogen-activated protein kinase (MAPK) pathways, p21 or βCatenin.
Activin A signaling is best known for playing a crucial role during embryogenesis and human
development. It also participates in stem cell differentiation and Epithelial-Mesenchymal
Transition (EMT). In the skin, Activin A has been shown to play an important role in promoting
wound healing and mediates inflammatory responses to injuries via the recruitment of immune
cells (macrophages and fibroblasts)19. We also know that intact Activin A signaling plays an
important role in controlling cell proliferation in normal, healthy epithelial cells by inhibiting
proliferation. However, it is increasingly believed that Activin A signaling plays a major role in
cancer formation and progression.
Activin A has been shown to participate in inflammation via the activation of NFκB, a
transcription factor that mediates inflammation. In advanced colorectal cancer, Activin A has
also been shown to lead to the degradation of p21, an important tumor suppression protein, using
NFκB and the protein MDM220.
In lung squamous cell carcinoma, Activin A has been shown to promote metastatic lung cancer
by inducing and maintaining EMT, which promotes the formation of cancer-initiating
mesenchymal cells21. In lung adenocarcinoma, a condition histologically comparable to
esophageal adenocarcinoma, elevated Activin A is correlated to poor patient prognosis19.
However, Activin A is known for having a complex role in the body. Indeed, Activin A has been
shown to behave entirely differently depending on the microenvironment. As much as Activin A
7

is known for its pro-metastatic and cancer-initiating roles, it has also been shown in many cases
to suppress tumor formation. In human breast cancer cells, for example, Activin A has been
shown to inhibit cancer cell proliferation and promote cell cycle arrest22. In addition, Activin
signaling and its growth suppressive effects are lost in colon cancer, but is intact and prometastatic in advanced colon cancer as explained above13.
Such examples show the characteristically complex, context-dependent action of Activin A
signaling. Whether it plays a prometastatic role or inhibits cancer formation, Activin A is clearly
involved in tumorigenesis. However, the role of Activin A signaling in the progression of
esophageal adenocarcinoma, particularly at the early stages induced by gastric reflux-related
injuries has not been characterized yet.
The goal of this research project is to characterize the role of Activin A signaling in the context
of the onset of GERD-related diseases. We also described the link between Activin A and the
inflammatory response to bile and acid injury in esophageal cells, as well as how this all plays
out in the progression to Barrett’s esophagus, an important risk factor for esophageal
adenocarcinoma. Due to the recent discoveries that bile salts and acid injuries increase
inflammatory cytokine signaling, we hypothesized that GERD-like injuries would cause an
increase in Activin A signaling, which promotes the inflammatory response and metaplasia to
BE.
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MATERIALS AND METHODS
Cell Culture
Human esophageal epithelial cells, STR, were cultured in Keratinocyte Serum-Free Medium
(KSFM) supplemented with 1 ng/ml Epidermal Growth Factor, 0.05 mg/ml Bovine Pituitary
Extract, and 1% penicillin streptomycin antibiotics (Gibco™, for Life Technologies, Inc.,
Carlsbad, CA). BAR-T cells, a human Barrett’s esophagus cells line (kind gift from Dr. Rhonda
Souza, Baylor Scott White) were cultured in Epithelial Cell Medium-2 supplemented with 5%
epithelial cell growth supplement-2 (EpiCGS-2) and 5% penicillin/streptomycin antibiotics
(ScienceCell™ Research Laboratories, Carlsbad, CA). All cells were incubated at 37°C with 5%
CO2. Treatment mimicking gastroesophageal reflux consisted of repeated exposure to acidified
medium (pH 4 – using 6N hydrochloric acid) and a 100 µM of cocktail of bile salts. The cocktail
included 20 µM of each, deoxycholic acid (MP Biomedicals, Santa Ana, CA), glycocholic acid,
taurocholic acid, sodium glycodeoxycholate and sodium glycochenodeoxycholate (All Sigma, St.
Louis, MO). To establish treatment-tolerant STRs, each treatment was performed for 4 minutes
in a 37°C incubator with 5% CO2, and then cells are allowed to recover for up to three days and
the surviving cells are propagated before the next treatment (Trt). The timeline in figure 3 shows
the treatment progression with time.

Figure 3: Timeline of bile salts and acid treatment.
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A8301, a selective TGFβ and Activin A signaling inhibitor (Tocris, Bristol, UK) was added to
the culture medium at a concentration of 1 µM. Recombinant Activin A (R&D Systems,
Minneapolis, MN) was used at 10 ng/ml. Both Activin A and A8301 treatments were performed
continuously for up to 10 days.
This study used the human esophageal cell line STR as a model for normal esophageal
epithelium in vitro. The human Barrett’s esophagus cell line BAR-T was used to model the
Barrett’s esophagus disease state in vitro.

Protein Analysis
Cellular Secretion using ELISA
Changes in the secretion of Activin A and TGFβ by normal esophageal STR cells as a result of
the bile/acid treatment was studied using the Activin A-specific and TGFβ-specific DuoSet®
ELISA assays by R&D Systems (Minneapolis, MN).
ELISA assays detect the amount of protein (Activin A or TGFβ) that cells secrete into their
environment (the surrounding medium in which they are grown) using specific antibodies. The
antibodies are also linked to the enzyme horseradish-peroxidase (HRP), which is used for
visualization. The specific amount of secreted ligand was calculated in pg/ml based on a standard
curve provided in the kit.
Cells were exposed to bile and acids for 4 minutes, as described above. They were then allowed
to recuperate for 30 minutes (Activin A) or 24 hours (TGFβ) in normal KSFM. After this, the
medium was collected and frozen at -80°C until further analysis.
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Cell Secretion using Cytokine Array
Changes in cellular secretion of cytokines of interest were measured using the RayBio® C-Series
Human Cytokine Antibody Array C6 (RayBiotech, Norcross, GA) and according to the
manufacturer’s protocol.
Protein Expression using Western Blotting
Changes in the expression and/or activation of the proteins involved in various pathways caused
by the treatments were analyzed via SDS PAGE followed by Western Blotting. To do so, cells
were lysed 30 minutes after the bile and acid treatment using IP Lysis buffer (150 mM NaCl, 50
mM Tris, pH 8.0, 1% Triton x-100, 1% NP-40) supplemented with a cOmplete™ EDTA-free
protease Inhibitor Cocktail tablet. Protein concentration was determined using the Pierce™ BCA
Protein Assay Kit (ThermoFisher Scientific, Waltham, MA). Subsequently, protein samples were
separated on a 30% acrylamide gel via SDS PAGE. Gels were transferred to a PVDF membrane
for western blotting. Proteins were visualized using primary antibodies and HRP-conjugated
secondary antibodies.
Protein
Cleaved PARP – Total PARP
Cleaved Caspase 9 – Total Caspase
9
pSmad
2,3 – total Smad 2,3

pERK 1/2 – total ERK 1/2
pStat1 – Stat1 (C-terminus)
pStat3 – Total Stat3
NFκB p65
COX2
Sox9

Role

Apoptosis marker
Apoptosis marker
Direct downstream target of canonical Activin A signaling
Involved in cell survival mechanism and non-canonical
Activin A Signaling
Inflammation-inducing transcription factors
Inflammation-inducing transcription factors
Transcription factor involved in Inflammation
Elevated during inflammation
Marker for columnar epithelial differentiation

Table 1: Markers used for Western Blot analysis19, 23, 24.
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Markers involved in the Activin A pathway, markers of stemness and reprogramming,
inflammation markers, and apoptosis markers were analyzed (table 1).

Gene Expression Analysis
The exposure of acidic bile salts to esophageal cells has been shown to induce significant DNA
damage25. We investigated the impact of acid and bile salts exposure on gene expression using
RNA isolation and two-step qRT-PCR. For this, total RNA was extracted and purified from
STR and BAR-T cells 30 minutes post-treatment via phenol and guanidine thiocyanate extraction
using the miRNeasy® Mini Kit (Qiagen, Santa Clara, CA) according to the manufacturer’s
protocol.

Name

TNFα
ILβ
Cox2
Sox9
LGR5
DCLK1

Forward - F
Reverse - R

F
R
F
R
F
R
F
R
F
R
F
R

Sequence (5'-3')

GAA TTC GGA CAC CAT GAG CAC TG
GGA TCC ACC GGT TCA CAG GGC AAT GAT CCC
ATG ATG GCT TAT TAC AGT GGC AA
GTC GGA GAT TCG TAG CTG GA
TGA GCA TCT ACG GTT TGC TG
TGC TTG TCT GGA ACA ACT GC
CAT GAG CGA GGT GCA CTC C
TCG CTT CAG GTC AGC CTT G
AAC AGT CCT GTG ACT CAA CTC AAG
TTA GAG ACA TGG GAC AAA TGC CAC
AGT CTT CCG ATT CCG AGT TGA G
CAG CAA CCA GGA ATG TAT TGG A
Table 2: Primers used in qRT-PCR

Reverse transcription was performed to obtain a cDNA library of the samples using the
QuantiTect® Reverse Transcription Kit (Qiagen, Santa Clara, CA). Real time qRT-PCR was
then performed using the QuantiTect SYBR® Green PCR kit by Qiagen. The genes Rpl13A and
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Eif3d were amplified as internal controls. We investigated several genes from the Activin A
pathway, inflammatory markers, and stem cell markers using this method (table 2)

Functional Assays
Functional assays were useful to determine the effect of changes in Activin A signaling on the
characteristics and properties of the cells. The functional assays used for this study were
proliferation assays as well as Boyden chamber assays.
Proliferation Assays
Proliferation assays were performed in order to determine the effect of the bile salts and acid
treatments, as well as the hypothesized increase in Activin A signaling, on the proliferative
capacity of the esophageal cells. This experiment was performed using a Click-iT® EdU kit
(Invitrogen, Carlsbad, CA) and according to the manufacturer’s protocol.
In this assay, a DNA intercalating agent (Click-iT® Alexa Fluor® azide) gets selectively
incorporated in the nucleus of actively dividing cells, which are in the S phase of the cell cycle,
therefore staining for actively proliferating cells. The assay was performed on cells after
repeated exposure to bile salts and acid and compared to an untreated control. The effect of
Activin A signaling on cell proliferation was studied using A8301, a selective Activin A
signaling inhibitor, and recombinant Activin A.
Particularly, the cells were exposed to EdU for 7 hours, and fixed immediately after. Cells were
stained with EdU for 30 minutes. Overall DNA was stained with Hoechst overnight at 4°C. For
analysis, the ratio of EdU positive cells to total cells (visualized using overall DNA staining) was
calculated. All calculations were made in triplicates and using biological replicates.
13

Additionally, the viability of the cells over time as a result of the repeated treatments was studied
using western blotting. For apoptosis markers, cell lysates were collected 4 hours post-treatment
(table 1).
Boyden Chamber Assays
The ability of cells to migrate through a reconstituted extracellular matrix (ECM) was measured
using BioCoat™ Matrigel® Invasion Chambers (Corning, Corning, NY) and according to the
manufacturer’s protocol.
These Boyden chambers use a chemoattractant to cause migration of cells through a porous
membrane and a reconstituted ECM. Particularly, 105 cells were plated on the top insert and
allowed to migrate through the Matrigel basement membrane. All conditions were performed in
triplicate inserts.
For analysis, the number of cells that had migrated through the ECM was counted in four
microscopic fields per insert (10X magnification), with three replicate inserts per condition. The
role of Activin A signaling was evaluated using A8301 and recombinant Activin A. The results
were used to describe the ability of cells to migrate through upon a extracellular protein matrix
such as an epithelial basement membrane26.

Statistical Analysis
Biostatistical analysis was performed using Prism version 6.00 for Mac. Experiments were
analyzed using Student’s t-tests or one-way ANOVAs. Statistical significance was set at p<0.05.
All experiments were done in triplicates or duplicates with at least three biological replicates.
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RESULTS
Characterization of Long-Term Treated Esophageal Epithelial Cells
STR esophageal epithelial keratinocytes were treated with acidified medium (pH 4 – reflecting
the acidity of stomach refluxate into the esophagus) and a cocktail of bile salts (see materials and
methods) as an in vitro model for acid reflux. In this model system, each exposure of cells to
acid and bile salts reflects a reflux episode in a GERD patient.
Figure 4: Long term-treated
esophageal epithelial cells
become tolerant after initial
apoptosis induced by
bile/acid. A-B: Apoptosis
markers Cleaved PARP and
Cleaved Caspase 9 were
drastically reduced after the
third treatment.

In order to mimic chronic exposure of the cells and determine any long-term changes, a protocol
for repeated and consecutive treatments was developed. To begin with, cells were not tolerating
the treatment very well: treated cells died significantly faster than control cells, particularly after
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a treatment. After each round of treatment, the surviving cells were kept and propagated for the
next treatment.
Interestingly, we observed in culture that after each consecutive treatment, cell death seemed to
gradually reduce.
In order to quantify this adaptation and apparent tolerance, cell lysates were collected after six
consecutive treatments and apoptosis markers were probed via western blotting (figure 4). It was
therefore determined that after a point of crisis, where significant cell death occurred, the
propagated cells were able to better tolerate the treatment. Such tolerant cells were used for all
further experiments.

Activin A Signaling is Induced upon Bile and Acid Injury and Promotes Wound
Healing
The first bit of evidence linking Activin A to acute inflammation came when Jones et al.
discovered that serum levels of Activin A increased significantly within 1 hour of an injection of
bacterial lipopolysaccharide (LPS) in sheep27. Since then, a variety of data and evidence suggests
that this cytokine plays an integral role in several inflammatory processes. However, the role of
Activin A signaling in GERD-related diseases has never been described, and formed the central
goal of this research project.
As mentioned, the Activin A pathway proceeds via two distinct routes. The first one goes
through the cytoplasmic Smad proteins, and is the canonical pathway of Activin A signaling.
Particularly, Smad2/3 gets phosphorylated during signaling, and the phosphorylated complex
gets translocated to the nucleus to act as a transcription factor and mediate signal response.
16

Interestingly, our data shows that bile salts and acid treatment of esophageal keratinocytes
triggers the canonical pathway of Activin A signaling within 30 minutes (figure 5-A).
Additionally, Activin A also proceeds via a non-canonical pathway for signaling, which involves
the mitogen-activated protein kinase (MAPK) pathways. Similarly, we also observed an increase
in phosphorylation of ERK protein, which is a direct target of the MAPK pathway, 30 minutes
after exposure to bile salts and acid (figure 5-B).

Figure 5: Acid and bile salts treatment activates Activin A signaling. A: Direct,
canonical downstream target Smad 2/3 gets phosphorylated, indicating Activin A
signaling. B: Non-canonical downstream target of Activin A, ERK, is also activated
upon treatment. C: Treated STR cells repeatedly secreted more Activin A.

In subsequent experiments using an Activin A inhibitor, we found that inhibiting Activin A
signaling does not inhibit ERK phosphorylation (see supplemental data). This would indicate
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that the activation of the non-canonical pathway of Activin A during acid reflux was not caused
by Activin A signaling alone.
To confirm that the bile and acid treatment triggered Activin A signaling, an ELISA assay was
performed using conditioned medium of cultured cells. Once more, the data showed an increase
in secreted Activin A 30 minutes post-treatment (figure 5-C). Together, our data suggests that
bile and acid treatment causes an increase in Activin A secretion by the esophageal keratinocytes
that disrupts the normal signaling of the Activin A pathway.
We subsequently hypothesized that the dysregulated signaling pathway could have an impact on
wound healing as a response of the epithelium to the bile and acid injury. We therefore tested if
the bile salts and acid treatment had caused any changes in the ability of cells to migrate through
an extracellular protein matrix such as the basement membrane of a stratified epithelium. To do

Figure 6: Migration of bile and acid treated cells on a reconstituted protein matrix.
A: Treated STR cells migrated faster through the reconstituted ECM. B: Upon
treatment with Activin A inhibitor A8301, cells migrated significantly slower. On
the other hand, normal cells treated with recombinant Activin A migrated faster.
18

so, treated cells were placed in a Boyden chamber and their ability to migrate through a
reconstituted extra-cellular matrix was measured.
In figure 6-A, the data showed that the bile and acid treatment caused changes in the cells
rendering them able to better migrate through a surrounding matrix.
A subsequent experiment was performed to determine if the increased migration through the
basement membrane is Activin A-dependent (figure 6-B). Here, the data shows that inhibiting
Activin A signaling using A8301 was capable of knocking the migration back down to normal
levels. On the contrary, treating cells with recombinant Activin A increased the migration across
the basement membrane significantly.
As mentioned above, the inhibitor A8301 shows broad-specificity for members of the TGFβ
superfamily. In other words, A8301 targets and inhibits receptors for Activin A signaling
(including Activin Receptors IB and IC), but also another receptor for the TGFβ ligand (TGFβ
Receptor IB). Signaling by the TGFβ ligand is therefore also inhibited by A8301.
In order to ensure specificity of the inhibitor for Activin A alone, we analyzed the amount of
TGFβ ligand secreted by STR cells. As such, we performed TGFβ-specific ELISA assays on
conditioned medium of both treated and untreated STR cells. Data from this experiment showed
very low, non-detectable levels of secreted TGFβ by STR cells across all conditions. Little to no
TGFβ was secreted by untreated STR cells, at 30 minutes as well as 24 hours post treatment.
This result suggested that the A8301 inhibitor used in these experiments specifically disrupted
Activin A signaling of STR cells.
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Chronic Inflammation Caused by Bile and Acid Injury and Activin A
In the early theories about the progression of GERD to Barrett’s esophagus and finally to
esophageal adenocarcinoma, much importance was accorded to the role of physical damage and
erosion that occurred during acid reflux. It was thought that this damage caused degradation of
normal surface epithelial cells, which would then promote the invasion of immune cells and
therefore cause inflammation10.
More recently, it has been shown that instead of causing erosion and mechanical injury, the
gastric reflux from GERD causes epithelial cells to release inflammatory cytokines, which would
themselves induce the inflammatory response, and be responsible for disease progression10.
In addition, previous literature has shown that increased Activin A signaling mediates increased
inflammation and fibrosis in injured tissue28, but this was never shown in esophageal epithelium.
We therefore hypothesized that the observed increase in Activin A signaling in the treated cells
could also trigger a disruption of inflammatory markers.
We used three different approaches to assess the impact of bile salts and acid on inflammatory
pathways. Namely, western blotting (figure 7 – A-D), inflammatory cytokine array (figure 7-E)
and qRT-PCR (figure 7-F). Interestingly, we found that bile salts and acid treated cells had
several upregulated inflammatory markers.
Particularly, the bile salts and acid treatment triggered more phosphorylation of the Stat1 and
Stat3 proteins, and caused an increase in expression of both NFκB and COX-2 (figure 7 – A-D).
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In addition, the cytokine array showed that the treatment caused a significant upregulation of
GM-CSF, INF-γ, the Interleukins 1α, 1β, 2, 3, 6, 7, and 16, as well as TNFα and TNFβ (figure 7E).
Finally, the treatment also caused an upregulation of gene expression for several inflammatory
cytokines, at the mRNA level (figure 7-F), namely for TNFα, IL-1β, as well as COX-2.
Interestingly, when the treated cells were also treated with the Activin A inhibitor A8301, the
upregulation of IL-1β and Cox-2 seemed to also be inhibited. However, treating normal cells
alone with recombinant Activin A did not cause any change in the expression of these
inflammatory cytokines. This data suggests that the increase in Activin A signaling caused by the
treatment may be partly responsible for the increased inflammation of the treated cells.
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In contrast, the inhibition of Activin A signaling actually caused an even greater increase in the
gene expression of TNFα. Conversely, adding recombinant Activin A to the normal STR cells

Figure 7: Bile salts and
acid treatment causes
increased inflammation
in STR cells. A-D:
Treatment with bile
salts and acid caused an
elevation of several
inflammatory markers.
E: Cytokine array on
conditioned medium of
treated cells showed
upregulation of a variety
of inflammatory
markers.
F: Several genes
involved in
inflammation were also
upregulated after the
bile and acid treatment.
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actually caused a decrease in TNFα expression.
Put together, our data suggests that even though it seems that Activin A may play a role in the
increased inflammation of STR cells (IL-1β, Cox-2), it is also likely that it is not the only
contributor. Additionally, the role of Activin A signaling in part may be indirect, as previously
reported (Activin A signaling can be context dependent).

Activation of Stem Cells as Result of Bile and Acid Injury
The proliferative capacity is one of the hallmarks of cancer, and important for the repair of an
injured epithelium. We performed experiments in order to measure cell growth and determine if
it is affected by the bile and acid treatment or the increased Activin A signaling.
In culture, we observed that the treatment tended to have a negative effect on cell proliferation.
After each treatment, cells were “shocked”, and it took a little time for them to recover. We
found that during this time, cells divided slower and therefore proliferated less.
We performed experiments to quantify this seemingly lower post-treatment proliferation. The
experiment involved a DNA intercalating agent EdU that is incorporated only in actively
dividing, proliferating cells. Using this method, we showed that the cells did in fact have a
reduced proliferation rate during the recovery time from an exposure to bile salts and acid
(figure 8-A and C). In addition, we analyzed whether or not the increase in Activin A signaling
affected cell proliferation in any way (figure 8-B). Treating the bile and acid-tolerant cells with
the Activin A inhibitor A8301 did not bring the proliferation rate back up to normal levels.
However, when we treated normal cells with recombinant Activin A, cell proliferation decreased
significantly, and it was comparable to the drop of the bile and acid treated cells. This data
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suggests that Activin A may also play a role in this decreased proliferation, but that the treatment
with bile and acid also damaged the cells enough to decrease their proliferation rate.
Figure 8: Bile salts and
acid treatment caused
reduction of proliferation
in STR cells. A: Treating
the cells with bile salts
and acid resulted in a
decrease in proliferation,
as indicated by a
decrease in actively
dividing cells. B: The
decrease in proliferation
caused by the bile salts
and acid treatment may
be Activin A- related.
Inhibiting Act. A
signaling did not bring
the proliferation back up,
but treating normal cells
with recombinant Act. A
also dropped the number
of proliferating cells. C:
Qualitative
representation of data in
frame A. Actively
proliferating cells are
stained in green.

Stem cells and progenitor cells are known for being slow cycling and proliferating slowly29. Our
finding about the reduced proliferation and therefore slower cell cycle in treated cells led us the
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hypothesize that the bile and acid treatment, as well as increased Activin A signaling, could lead
to an resurgence of stem cell features, and increased plasticity, possibly involving dedifferentiation back into an epithelial stem cell-like state. This hypothesis is consistent with the
latest research on the potential source of Barrett’s esophagus stem cells as well as theories on

Figure 9: Treatment with bile salts and acid induces upregulation of stem cell markers.
A-C: Treated cells displayed an increase in stem cell markers. Inhibition of Act. A
signaling using A8301 in treated cells tends to bring back the stem cell markers to
normal levels, indicating a potential Activin A involvement.

plasticity among differentiated adult epithelial cells. We investigated this hypothesis using
western blotting and qRT-PCR, looking at the levels of stem cell markers in the treated cells
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(figure 9). Interestingly, we observed an increase in Sox9 in the bile and acid treated cells
(figure 9-A). Sox9 is known for being overexpressed in Barrett’s esophagus tissues. In
esophageal squamous tissues, it is a known marker for columnar metaplasia24.
We also found that treating the cells with bile salts and acid significantly increased the stem cell
markers DCLK and LGR5. LGR5 is known to be overexpressed in gastrointestinal stem cells
and for being a marker for intestinal metaplasia30. DCLK has also been shown to be a
gastrointestinal stem cell marker31.
Finally, another interesting point was that inhibiting Activin A signaling using A8301 usually
caused a diminishing of these upregulations. However, Activin A alone usually was not enough
to cause a significant increase in stem markers (figure 9 – A-B), but did trigger an increase in
LGR5 that was similar to the bile and acid treatment (figure 9-C).
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DISCUSSION & CONCLUSIONS
The data presented in this paper shed light on the involvement of Activin A signaling in GERDassociated diseases. Our results suggest that repeated bile salts and acid exposure on esophageal
squamous keratinocytes triggers an increase in secretion of the Activin A cytokine. This causes
changes in several cell characteristics including cell invasion and the activation of stem cell
markers as part of the injury repair.
Dysregulated cytokine signaling has been previously shown to be responsible for inflammation
in a GERD-like setting10, and Activin A itself has been shown to promote inflammation and
fibrosis in other diseases and in skin wound healing19, 20, 28. This study was the first performed on
the Activin A cytokine in the context of gastroesophageal reflux disease.
Our data provides support for the latest theory about the onset of GERD-related disease, namely
that esophageal epithelial cells can be responsible for promoting inflammation through cytokine
secretion upon being injured by bile salts and acid from the gastric reflux. In addition, the data
shown here provides the first evidence that the Activin A cytokine is involved in promoting
inflammation in a GERD-related context. Indeed, we found Activin A to be increasingly secreted
upon bile salts and acid injuries. We also found that several inflammatory markers were
upregulated. Upon inhibiting Activin A signaling in the bile and acid treated cells, we observed
that several inflammatory markers were in turn significantly reduced back to near normal levels.
The origin of Barrett’s esophagus and the source of the progenitor stem cells that eventually lead
to BE remains unknown and is the subject of intense research. Briefly, there are have been
several proposed theories. The first one proposes that the acid and bile salts from the gastric
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reflux injures the esophageal epithelium, and causes mature, differentiated squamous cells to
undergo molecular reprogramming into a columnar type of epithelium, a process called
transdifferentiation. This theory proposes the same idea for immature esophageal epithelial cells,
found in the basal layer epithelium tissues. In this case, the gastric reflux injury causes these
undifferentiated cells to develop into columnar cells rather than squamous cells. This process is
called transcommitment24.
The other theories include that Barrett’s esophagus progenitor cells actually come from the
gastric cardia. Stem cells from the gastric cardia, which are programmed columnar epithelial
cells, are proposed to have migrated up into the esophagus and caused BE. Another theory
proposes that residual embryonic stem cells expand into the esophagus and form the source of
the BE tissue. Another theory is that intermediate-type cells from the squamo-columnar junction
form the source of the BE cells. Finally, it is suspected that circulating bone marrow stem cells
may settle into the injured tissue and differentiate into columnar, Barrett’s tissue24.
Our data gives support to the theory that BE stem cells originate from the existing squamous
epithelial tissue. The cells used in our model are differentiated squamous esophageal epithelial
cells. However, upon treating them with a GERD-like mixture of bile salts and acid, gene
expression for the gastrointestinal stem cell markers DCLK and LGR5 was elevated. In addition,
the epithelial columnar metaplasia marker Sox9 was also upregulated. These results provide
evidence for the transdifferentiation theory of BE stem cell source.
The concept of transdifferentiation is tightly linked to a brand-new theory in the field termed
paligenosis. In short, the paligenosis theory states that much like the apoptosis pathway,
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differentiated cells contain a molecular pathway, which, when triggered by injury, enables cells
to achieve dedifferentiation into a progenitor cell-like state, rendering them able to change into a
different cell type5, 32-34.
The pathway first involves a metaplastic-inducing injury such as gastric reflux. Then, this causes
a decrease in the mTORC1 pathway activity and a substantial upregulation of lysosomes. Then,
damage-associated genes and stem cell genes, such as for example Sox9, are activated. Finally,
the mTORC1 pathway is reactivated and the cell re-enters the cell cycle5. This pathway has been
shown to be conserved across many tissues and cell types. Paligenosis has therefore been
proposed as a mechanism as conserved as the apoptosis mechanism, across all cells32.
This theory gives an explanation to the plasticity observed in cells from many different tissues,
including the esophagus. In the context of esophageal diseases, paligenosis would enable what
we originally believed as terminally differentiated cells, such as those in the esophageal
squamous epithelium, to undergo a metaplastic change and give rise to a metaplastic tissue of a
different cell type such as the one seen in BE.
The data presented in this paper do support the notion of paligenosis. Our findings of the
upregulation of stem cell markers and the decrease in proliferation of differentiated esophageal
epithelial cells caused by exposure to bile salts and acid, both support this new theory. A future
direction for this study would be to dive deeper into the link between gastric reflux-related
diseases, transdifferentiation, transcommitment and paligenosis. This could provide more
information into the origin of metaplastic Barrett’s esophagus cells, which are important
contributors to the formation of esophageal adenocarcinoma.
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APPENDIX: SUPPLEMENTAL DATA
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Figure 10: A8301 can inhibit the upregulation of canonical Activin A signaling, but not of non-canonical
signaling. A: Canonical Activin A signaling is upregulated by bile salts and acid exposure. A8301 inhibitor
can bring this upregulation back down. B: Non-canonical Activin A signaling is upregulated by bile salts
and acid exposure. A8301 inhibitor was unable to bring it back down.
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